ArticleCNS neuroscience & therapeutics2026
Multimodal Integration of Gait Dysfunction, Amyloid PET, and Plasma Biomarkers for Differentiating Etiological Subtypes in Mild Cognitive Impairment.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate gait characteristics and plasma biomarkers in individuals with mild cognitive impairment (MCI) stratified by amyloid-β (Aβ) positivity on positron emission tomography (PET), and to evaluate the predictive value for Alzheimer's disease (AD)-related MCI.
methodsA total of 168 participants were enrolled, including 50 amyloid PET-negative MCI (MCI-), 51 amyloid PET-positive MCI (MCI+), and 61 cognitively normal (CN) individuals. Gait assessments were conducted using a multi-sensor motion analysis system during dual-task paradigms (cognitive load superimposed on locomotion). Plasma samples were analyzed for neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau at threonine 217 (p-tau217) via ultra-sensitive immunoassays.
resultsGait analyses identified 125 features, with 69 distinguishing MCI+ from CN and 36 differentiating MCI+ from MCI-. Receiver operating characteristic (ROC) analyses showed that dual-task gait under the countdown and animal-naming conditions (gait-countdown [GCD] and gait-animal naming [GAN]) discriminated MCI+ from CN with an AUC of 0.850. The combined models integrating GCD and GAN with plasma GFAP or p-tau217 yielded AUCs of 0.919 and 0.951, respectively. Similarly, GCD&GAN features demonstrated an AUC of 0.862 for distinguishing MCI+ from MCI-, with GFAP (AUC = 0.933) and p-tau217 (AUC = 0.986) enhancing predictive performance.
conclusionThis study provides evidence that dual-task gait assessments, when combined with plasma biomarkers such as GFAP and p-tau217, may improve the discriminatory power for identifying AD-related MCI. The integration of biomechanical and molecular markers holds promise for advancing early detection strategies and therapeutic monitoring in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.